Successful treatment of atypical adult pityriasis rubra pilaris with oral alitretinoin

Pampín, A.; Fuente, E. Gómez-de la; Gutiérrez, María Dolores Caro; López-Estebaranz, J.L.

doi:10.1016/j.jaad.2013.01.036

Cited by 15 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We could demonstrate that alitretinoin 30 mg/day was highly effective in 4 of 5 cases when alitretinoin was applied to treat PRP for the first time. This observation is consistent with previous single PRP case reports (8)(9)(10).…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Alitretinoin (9-cis Retinoic Acid) is Effective Against Pityriasis Rubra Pilaris: A Retrospective Clinical Study

Amann¹,

Susic²,

Glüder³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) is an uncommon cutaneous disease with disorder of keratinisation. Up to now, systemic retinoids like acitretin or isotretinoin seem to be the most effective therapeutic agents. However, no large trials on this rare disease have been published and no standardised treatment has been established so far. Recently, single case reports demonstrate beneficial effects of alitretinoin (9-cis retinoic acid) in patients with PRP. We performed a retrospective observational analysis of type I adult-onset patients with PRP (n = 5) treated with systemic alitretinoin in our department. Alitretinoin was highly effective in the treatment of PRP in 4 of 5 cases. PASI score was reduced significantly in the alitretinoin responders. We assume that alitretinoin could serve as an additional effective systemic treatment option for type I adult-onset PRP.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Systemic retinoids like acitretin or isotretinoin seem to be the most effective therapeutic agents but satisfying clinical response does not always occur (7). Recently, 3 single case reports were published considering alitretinoin as a very successful and well-tolerated treatment option for patients with PRP (8)(9)(10).…”

mentioning

confidence: 99%

Alitretinoin (9-cis Retinoic Acid) is Effective Against Pityriasis Rubra Pilaris: A Retrospective Clinical Study

Amann¹,

Susic²,

Glüder³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…Moreover, systemic therapy with acitretin (25–50 mg/day) led to a partial to marked clinical response . Recently, a small case series demonstrated that 30 mg/day alitretinoin was highly effective, which has been confirmed by other case reports . Alitretinoin can be effective in the treatment of juvenile forms of PRP according to some case reports …”

Section: Uv Therapy and Systemic Treatment Options (Without Biologics)mentioning

confidence: 86%

“…45 Recently, a small case series demonstrated that 30 mg/day alitretinoin was highly effective, 8 which has been confirmed by other case reports. [63][64][65] Alitretinoin can be effective in the treatment of juvenile forms of PRP according to some case reports. 66,67 In clinical practice, the recommended daily dose of isotretinoin for adults with PRP is 0.5-1 mg/kg per day and 0.3-0.5 mg/kg per day of acitretin and etretinate.…”

Section: Uv Therapy and Systemic Treatment Options (Without Biologics)mentioning

confidence: 99%

Pityriasis rubra pilaris: algorithms for diagnosis and treatment

Roenneberg

Biedermann

2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages and also children. The clinical appearance of PRP is highly variable, as is the individual prognosis. Therefore, stratifying PRP into six disease subtypes represents a first step to personalized medicine for this rare inflammatory skin disease. The next step should be to associate specific therapeutic strategies with these subtypes of PRP. However, no randomized, controlled trials on the treatment of PRP have been performed. Consequently, the actual treatment algorithm for PRP will be based on clinical experience, small case series and case reports. The majority of published evidence is on type I PRP, whereas the treatment experience for other clinical types of PRP is still sparse and has to be gained. Nevertheless, it is now time to start developing valid algorithms as a basis for the diagnosis and treatment of PRP based on the data available. This review makes use of algorithms developed in psoriasis and atopic eczema and puts together recent insights into the pathogenesis, diagnosis and treatment experience of PRP. The innovative intention of this appraisal is to develop a structured algorithm for PRP treatment that should be further developed going forward.

show abstract

“…Alitretinoin suppresses cytokine production in keratinocytes and fibroblasts, and down‐regulates leukocyte activity . Eight cases of PRP treated with systemic alitretinoin have been reported , and all cases except one were responsive to oral alitretinoin. Those cases were adult‐onset PRP refractory to conventional therapy and some were unresponsive to systemic retinoids.…”

Section: Discussionmentioning

confidence: 99%